Similar articles

• Revision of the guidelines for diagnosis and therapy of chronic lymphocytic leukemia (CLL).

  Eichhorst B, Hallek M. Eichhorst B, et al. Best Pract Res Clin Haematol. 2007 Sep;20(3):469-77. doi: 10.1016/j.beha.2007.02.002. Best Pract Res Clin Haematol. 2007. PMID: 17707834
• Current guidelines in defining therapeutic strategies.

  Ferrajoli A, Keating MJ. Ferrajoli A, et al. Hematol Oncol Clin North Am. 2004 Aug;18(4):881-93, ix. doi: 10.1016/j.hoc.2004.04.006. Hematol Oncol Clin North Am. 2004. PMID: 15325704 Review.
• MRD in CLL.

  Hillmen P. Hillmen P. Clin Adv Hematol Oncol. 2006 May;4(5):6-7; discussion 10; suppl 12. Clin Adv Hematol Oncol. 2006. PMID: 16830420 No abstract available.
• Is MRD eradication a desirable goal in CLL?

  Moreno C, Ritgen M, Rawstron A. Moreno C, et al. Best Pract Res Clin Haematol. 2010 Mar;23(1):97-107. doi: 10.1016/j.beha.2010.01.005. Best Pract Res Clin Haematol. 2010. PMID: 20620974 Review.
• Minimal residual disease assessment in chronic lymphocytic leukaemia.

  Sayala HA, Rawstron AC, Hillmen P. Sayala HA, et al. Best Pract Res Clin Haematol. 2007 Sep;20(3):499-512. doi: 10.1016/j.beha.2007.03.004. Best Pract Res Clin Haematol. 2007. PMID: 17707836 Review.